International Journal of Diabetes Research

International Journal of Diabetes Research publishes reports of experimental and clinical research on diabetes mellitus and metabolism. Original contributions on morphological, biochemical, physiological and clinical aspects of research on diabetes and metabolism are welcome. The role of the journal is to provide a venue for dissemination of knowledge and discussion of topics related to diabetes clinical research and patient care.

Ian Martins

Editor-in-Chief of International Journal of Diabetes Research

Post-doctoral Fellow, Edith Cowan University, Australia

Research Areas

Cell Biology, Lipoproteins, Liver, Steatosis, Diet and Leptin and Amyloid Beta , Cholesterol, Drugs,Brain, Lipid Metabolism, Protein Aggregation and Interactions ,Obesity, Cognition, Apolipoprotein E, Amyloid Beta Meta Bolism, Hyperphagia, Sterols, Micros


1989Ph.DUniversity of Western Australia
1986M.ScUniversity of Western Australia
1984B.ScUniversity of Western Australia


1994-1999Consultant to Inovax Ltd. (Scientific Advisor) Inovax, Australia

Publications: Conferences/Workshops/Symposiums/Journals/Books

[1]  Sharman MJ, Moirci M, Hone E, Berger T, Taddei K, Martins IJ, Lim WL, Singh S, Wenk MR, Ghiso J, Baubaum JD, Gandy S and Martins RN, APOE genotype results in differential effects on the peripheral clearance of amyloid-beta42 in APOE knock-in and knock-out mice. Jourmal of Alzheimer's disease. 21(2):403-9.2010. Impact factor = 4.0)
[2]  Sharman MJ, Guanghou Shui, Aaron Z. Fernandis, Wei Ling F. Lim, Tamar Berger, Eugene Hone, Kevin Taddei, Ian J. Martins, Jorge Ghiso, Joseph Buxbaum, Sam Gandy, Markus R. Wenk and Ralph N. Martins. Profiling brain and plasma in human lipids in human APOE ε2, ε3 and ε4 knock-in mice using electrospray ionization mass spectrometry. Journal of Alzheimer's Disease. 20(1);105—11. 2010. Impact Factor = 5.0 )
[3]  Taddei K, Laws SM, Verdile G, Munns S, D'Costa K, Harvey AR, Martins IJ, Hill F, Levy E, Shaw JE and Martins RN. Novel phage peptides attenuate beta amyloid-42 catalysed hydrogen peroxide production and associated neurotoxicity. Neurobiology of Aging. 31(2):203-14. 2010. Impact Factor = 6.1)
[4]  Martins IJ, Berger T, Sharman MJ, Verdile G, Fuller SJ and Martins RN. Cholesterol metabolism and transport in the pathogenesis of Alzheimer's disease. Journal of Neurochemistry. 2009. Cholesterol metabolism and transport in the pathogenesis of Alzheimer's disease. Journal of Neurochemistry. 111:1275-308. 2009. Impact factor = 4.0)
[5]  Bates KA, Sohrabi H, Rodrigues M, Beilby J, Dhaliwal S, Taddei K, Criddle, Wraith M, Howard M, Martins G, Paton A, Mehta P, Foster J, Martins IJ, Lautenschlager N, Mastaglia F, Laws SM and Martins RN.Association of cardiovascular factors and Alzheimer's disease plasma amyloid-beta protein iln subjective memory complainers Journal of Alzheimer's Disease. 17(2): 305-18.2009. Impact Factor = 5.0)
[6]  Martins IJ, Hone E, Foster JK, Sunram-Lea SI, Gnjec A, Fuller SJ, Nolan D, Gandy SE, Martins RN. Apolipoprotein E, cholesterol metabolism, diabetes and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Molecular Psychiatry. 11: 721-36; 2006. Review Impact Factor = 12.5 )
[7]  Hone E, Martins IJ, Jeoung M, Ji TH, Gandy SE and Martins RN. (2005). Alzheimer's disease Aβ peptide modulates apo E isoform specific effects on receptor binding. Journal of Alzheimer's Disease. 7 :303-14; 2005. Impact Factor =5.0 )
[8]  Martins IJ, Redgrave TG (2004) Obesity and post-prandial lipid metabolism. Feast or Famine? J Nutr Biochem. 15:130-41 Review. Impact Factor = 4.35 )
[9]  Hunter M, Bernard R, Freitas E, Boyer A, Morar B, Martins IJ, Tournev I, Jordanova A, Guergelcheva V, Ishpekova B, Kremensky I, Nicholson G, Schlotter B, Lochmuller H, Voit T, Colomer J, Thomas PK, Levy N, Kalaydjieva L, (2003) Mutation screening of the N-myc downstream-regulated gene 1 (NDRG1) in patients with Charcot-Marie-Tooth Disease. Human Mutation 22:129-35. Impact Factor = 7.0 )
[10]  Dane-Stewart CA, Watts GF, Barrett PH, Stuckey BG, Mamo JC, Martins IJ, Redgrave TG (2003) Chylomicron remnant metabolism studied with a new breath test in postmenopausal women with and without type 2 diabetes mellitus. Clinical Endocrinology 58:15-20. Impact Factor = 3.8 )
[11]  Hone E, Martins, IJ, Fonte J, Martins RN (2002) Apolipoprotein E influences amyloid-beta clearance from the murine periphery. Journal of Alzheimer's Disease. 5:1-8 . Impact Factor = 5.0 )
[12]  Dane-Stewart CA, Watts GF, Mamo JC, Barrett PH, Martins IJ, Dimmitt SB, Redgrave TG (2002) Effect of Simvastatin on markers of triglyceride-rich lipoproteins in familial hypercholesterolemia. European Journal of Clinical Investigation. 32:493-499 Impact Factor = 3.0 )
[13]  Martins IJ, Tran JML Redgrave TG (2002) Food restriction normalizes chylomicron remnant metabolism in murine models of obesity as assessed by a novel stable isotope breath test. Journal of Nutrition 132:176-181 Impact Factor = 3.7 )
[14]  Chan DC, Watts GF, Barrett PHR, Martins IJ, James AP, Mamo JCL, Mori TA, Redgrave TG (2002) Effect of atorvastatin on chylomicron remnant metabolism in visceral obesity: a study employing a new stable isotope breath test . J. Lipid Res. 43:706-712 Impact Factor = 4.4 )
[15]  Watts GF, Barrett PHR, Marais AD, Dane-Stewart CA, Martins IJ, Dimmitt SB, Redgrave TG (2001) Chylomicron remnant metabolism in familial hypercholesterolemia studied with a stable isotope breath test. Atherosclerosis 157:519-523 Impact Factor = 4.6 )
[16]  Watts GF, Chan DC, Barrett PH, Martins IJ, Redgrave TG (2001) Preliminary experience with a new stable isotope breath test for chylomicron remnant metabolism: a study in central obesity. Clinical Science. 101:683-90 Impact Factor = 4.2 )
[17]  Redgrave TG, Watts GF, Martins IJ, Barrett PHR, Mamo JCL, Dimmitt SB, Marais AD (2001) Chylomicron remnant metabolism infamilial dyslipidemias studied with a remnant-like emulsion breath test. J. Lipid. Res. 42:710-5 Impact Factor =4.4 )
[18]  Martins IJ, Hone E, Chi C, Seydel U, Martins RN, Redgrave TG (2000) Relative roles of LDLr and LRP in the metabolism of chylomicron remnants in genetically manipulated mice. J. Lipid. Res. 41:205-213. Impact Factor = 4.4 )
[19]  Martins IJ, Vermuellen R, Redgrave TG (2000) Relative roles of mitochondrial and peroxisomal fatty acid oxidation in the metabolism of chylomicron remnants in rats and mice as assessed by a stable-isotope breath test. Atherosclerosis.150:13-20. Impact Factor =4.6 )
[20]  Phan CT, Mortimer B-C, Martins IJ, Redgrave TG, (1999) Dietary fats, influences on the clearance of chylomicrons in the rat. Am.J.Clin.Nutr. 69:1151-61. Impact Factor = 7.7 )
[21]  I.J. Martins and T. G. Redgrave. 1998. A 13CO2 breath test for the assessment of remnant metabolism in mice. J Lipid. Res. 39: 693-699. Impact Factor = 4.4 )
[22]  I.J. Martins, C. Vilchèze, B-C. Mortimer, R. Bittman, and T. G. Redgrave. 1998. Sterol side chain length and structure affect the clearance of chylomicron-like emulsions in rats and mice. J. Lipid Res. 39: 302-312. Impact Factor =4.4 )
[23]  B.J. Zeng, B-C. Mortimer, I.J. Martins, U. Seydel and T.G. Redgrave. 1998. Chylomicron remnant uptake is regulated by the expression and function of heparan sulfate proteoglycan in hepatocytes. J.Lipid. Res.39: 887-905. Impact Factor = 4.4 )
[24]  B-C. Mortimer, I.J. Martins, B.J. Zeng and T.G. Redgrave. 1997. Use of gene-manipulated models to study the physiology of lipid transport. J. Clin. Exp. Pharm. Phsyiol. 24: 281-285. Impact Factor = 2.2 )
[25]  I.J. Martins, B-C. Mortimer and T. G. Redgrave. 1997. Effect of the ACAT inhibitor CL 277,082 on apolipoprotein B48 transport in mesenteric lymph and on the plasma clearance of chylomicrons and remnants. Arteriosclerosis. Thrombosis and Vascular Biology. 17: 211-216. Impact Factor = 7.6 )
[26]  I.J. Martins, B-C. Mortimer, J. Miller and T. G. Redgrave. 1996. Effects of particle size and number on the plasma clearance of chylomicrons and remnants. J. Lipid. Res. 1996. 37: 2696-2705. Impact Factor = 4.4 )
[27]  T.G. Redgrave, B. C. Mortimer, I. J. Martins. Receptor-ligand interactions in the hepatic uptake of chylomicron remnants studied with genetically manipulated mice. In: Hepatic endocytosis of lipids and proteins. 34 Suppl 1996.3. 105-107. Zietschrift fur Gastroenterologie. Impact Factor =0.88 )
[28]  Redgrave, T.G., I. J. Martins, and B-C. Mortimer. 1995. Measurement of expired carbon dioxide to assess the metabolism of remnant lipoproteins. J. Lipid Res. 36: 2670-2675. Impact Factor = 4.4 )
[29]  Mortimer, B-C., D.J. Beveridge, I.J. Martins and T.G. Redgrave. 1995. Intracellular localization and metabolism of chylomicron remnants in the livers of low density lipoprotein receptor-deficient mice and apo E-deficient mice. Evidence for slow metabolism via an alternative apo E dependent pathway. J. Biol. Chem. 48: 28767-28776. Impact Factor = 5.5 )
[30]  I.J.Martins, A.J. Sainsbury, J.C.L. Mamo and T.G. Redgrave. 1994. Lipid and apolipoprotein B48 transport in mesenteric lymph and the effect of hyperphagia on chylomicron clearance in insulin-deficient rats. Diabetologia. 37: 238-246. Impact Factor = 6.42 )
[31]  I.J. Martins and T. G. Redgrave. Measurement of chylomicron remnant metabolism by a newly developed breath test for the evaluation of post-prandial atherogenesis. The Ist International workshop on Atherosclerosis Research of Australian-Japanese co-operation. Tokyo Jan 20-21. 1994. 74-77. Editors: Akira Yamamoto and P.J. Nestel.
[32]  B.C. Mortimer, D.J.Holthouse, I.J.Martins, R.V. Stick and T.G. Redgrave. 1994. Effects of triacylglycerol saturated acyl chains on the clearance of chylomicron-like emulsions from the plasma of the rat. Biochim. Biophys. Acta. 1211: 171-180. Impact Factor = 4.2 )
[33]  Y. Chen, M. A. Burton, I.J. Martins, J.P.Coode, S.Napoli and B. N. Gray. 1992. Evaluation of Ion-exchange microspheres as carriers for the anti-cancer drug Doxorubicin: In vitro studies. J. Pharm. Pharmacol. 44: 211-215. Impact Factor =1.85 )
[34]  S.Napoli, I.J. Martins, M. A. Burton,Y. Chen, J.P.Coode, S.Napoli and B. N. Gray. 1992.Dose response and toxicity of doxorubicin microspheres in a rat tumour model.Anti-cancer Drugs.3 (1): 47-53. Impact Factor =2.36 )
[35]  I.J.Martins and T.G. Redgrave. 1992. The effects of Insulin-deficiency on the metabolism of High Density Lipoprotein Phospholipids in Rats. Biochem J. 281: 851-857. Impact Factor = 4.4 )
[36]  I.J.Martins, L. Hopkins, C. Joll and T.G. Redgrave. 1991. Interactions between triacylglycerol-rich Model lipoproteins and High Density lipoproteins in rat, rabbit and man. Biochim. Biophys.Acta. 1081: 328-338. Impact Factor = 4.18 )
[37]  N.P. Lenzo, I.J. Martins, B. C. Mortimer and T.G. Redgrave. 1988. Effects of phospholipid composition on the metabolism of triacylglycerol, cholesteryl ester and phosphatidylcholine from lipid emulsions injected intravenously in rats. Biochim. Biophys. Acta. 960: 111-18. Impact Factor = 4.18 )
[38]  I.J. Martins, N.P. Lenzo and T.G. Redgrave. 1989. Phosphatidylcholine metabolism after transfer from lipid emulsions injected intravenously into rats. Implications for High Density lipoprotein metabolism. Biochim. Biophys. Acta. 1005: 217-224. Impact Factor = 4.18 )